ইউরোপীয় ইউনিয়ন -
আইসল্যান্ডীয় -
EMA (European Medicines Agency)
vydura
pfizer europe ma eeig - rimegepant - mígreni kvilla - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
darunavir medical valley filmuhúðuð tafla 600 mg
medical valley invest ab - darunavir propylene glycolate - filmuhúðuð tafla - 600 mg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
desirett (desogestrel) filmuhúðuð tafla 75 míkróg
exeltis healthcare s.l. - desogestrelum inn - filmuhúðuð tafla - 75 míkróg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
gestrina filmuhúðuð tafla 75 míkróg
teva b.v.* - desogestrelum inn - filmuhúðuð tafla - 75 míkróg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
cerazette filmuhúðuð tafla 75 míkróg
n.v. organon* - desogestrelum inn - filmuhúðuð tafla - 75 míkróg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
melleva filmuhúðuð tafla 0,15 mg/0,03 mg
exeltis healthcare s.l. - levonorgestrelum inn; ethinylestradiolum inn - filmuhúðuð tafla - 0,15 mg/0,03 mg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
mercilon tafla 150 míkróg/20 míkróg
n.v. organon* - desogestrelum inn; ethinylestradiolum inn - tafla - 150 míkróg/20 míkróg
আইসলণ্ড -
আইসল্যান্ডীয় -
LYFJASTOFNUN (Icelandic Medicines Agency)
primolut n tafla 5 mg
bayer ab* - norethisteronum inn - tafla - 5 mg
ইউরোপীয় ইউনিয়ন -
আইসল্যান্ডীয় -
EMA (European Medicines Agency)
orserdu
stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
ইউরোপীয় ইউনিয়ন -
আইসল্যান্ডীয় -
EMA (European Medicines Agency)
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.